RxDoctor Payments Data

Eric Payne, MD

Internal Medicine · Franklinton, LANPI 1356306864

Payments from drug & device makers

$1,221in general payments, 2019–2025

Across 35 payments — averaging $34.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$474
  • Mentor Worldwide LLC$269
  • Bayer$167
  • Renalytix AI, Inc.$86
  • AstraZeneca$38
  • Pfizer$32
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$1,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,221 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$84,211
Medicare patients
172
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$119,118
LinzessLinaclotide66$54,936
JardianceEmpagliflozin49$47,339
RybelsusSemaglutide25$33,479
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$30,472
EliquisApixaban39$27,592
TrulicityDulaglutide20$26,140
VraylarCariprazine Hcl13$23,977
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,070
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$19,089
Oxymorphone Hcl ErOxymorphone Hcl13$16,398
JanuviaSitagliptin Phosphate28$16,248
XareltoRivaroxaban14$16,116
KerendiaFinerenone22$13,667
Combivent RespimatIpratropium/Albuterol Sulfate13$11,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$152,597106 claims
AbbVieLinzess, Vraylar, Armour Thyroid$474$82,159147 claims
AstraZenecaBreztri Aerosphere$38$30,47237 claims
PfizerEliquis$32$27,59239 claims
Lilly USA, LLCTrulicity$31$26,14020 claims
GSKTrelegy Ellipta$23$20,07023 claims
BayerKerendia$167$13,66722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Franklinton

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →